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Summary
OBJECTIVES—To determine predictors of mortality in children on anti-retroviral therapy (ART)
who attended the Paediatric HIV Clinic at Kamuzu Central Hospital in Lilongwe, Malawi.
METHODS—Retrospective case cohort study by chart review of children who had started ART
between October 2004 and May 2006. Bivariable and multivariable analysis were performed with
and without defaulters to evaluate associations according to vital status and to identify independent
predictors of mortality.
RESULTS—Forty-one of 258 children (15.9%) were deceased, 185 (71.7%) were alive, and 32
(12.4%) had defaulted: 51% were female, 7% were under 18 months, 26% were 18 months to 5 years,
and 54% were >5 years of age. Most were WHO stage III or IV (56% and 37%, respectively). On
multivariate analysis, factors most strongly associated with mortality and defaulting were age <18
months [hazards ratio (HR) 2.11 (95% CI 1.0–4.51)] and WHO stage IV [HR 2.00 (95% CI 1.07–
3.76)].
CONCLUSIONS—To improve outcomes of HIV-positive children, they must be identified and
treated early, specifically children under 18 months of age. Access to infant diagnostic procedures
must be improved to allow effective initiation of ART in infants at higher risk of death.
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Introduction
Malawi is a nation of more than 13.5 million people, where more than 14% of young adults
are infected with HIV (United States Central Intelligence Agency 2007). Up to 90 000 of the
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approximately 1 million HIV-infected individuals in Malawi are children (UNAIDS 2006),
who become infected prenatally, perinatally during delivery, or postnatally via breast milk. In
Malawi, HIV/AIDS has reduced the life expectancy at birth to 43 years (United States Central
Intelligence Agency 2007).
Anti-retroviral therapy (ART) can drastically improve survival of HIV-infected individuals,
even in poor settings (Mocroft et al. 1998; Egger et al. 2002; Eley et al. 2006; Little et al.
2007; Walker et al. 2007). The Malawian Ministry of Health has greatly increased ART
distribution since June 2004 through a free anti-retroviral drug provision programme.
Distribution to adults has progressed well: 146 856 individuals were receiving therapy by
December 2007 (Lowrance et al. 2007). But treatment of children has lagged behind: only 8%
of the total ART distribution is given to children under 13 years of age, although children
comprise 10–15% of cases, according to national estimates (Makombe et al. 2006; MoH
Malawi 2007). As of December 2007, 11 865 children had been started on ART (MoH Malawi
2007).
Mortality remains relatively high in Malawians receiving ART. Approximately 10–15% of
individuals die within 15 months of ART initiation, most within the first 3 months (Etard et
al. 2006; Zachariah et al. 2006; Zijlstra & van Oosterhout 2006; Callens et al. 2009). Among
adults on ART, anaemia, low body mass index, low CD4 count (<50) or advanced WHO staging
(IV), and Kaposi's sarcoma predict mortality (Zachariah et al. 2006; Boyd & Cooper 2007;
Walker et al. 2007). In children younger than 15 years, WHO stage IV, severe wasting, low
total lymphocyte count, and low CD4 count and percentage appear to contribute to early
mortality (HIV Paediatric Prognostic Markers Collaborative Study 2005; Bolton-Moore et
al. 2007; Bong et al. 2007; Kiboneka et al. 2008). Demographic factors may also play an
important role in children's survival (Ntozi et al. 1997). There is not enough information on
HIV care and clinical outcomes in children, mainly because relatively few children receive
ART. Hence our aim was to examine the characteristics of HIV-infected children receiving
ART in Lilongwe, Malawi and to determine factors associated with mortality.
Materials and methods
Study design
We conducted a retrospective case cohort study using data from the paper medical record
system in the Paediatric HIV Clinic at Kamuzu Central Hospital (KCH). In a case cohort design,
a sample of the entire available cohort is selected. This subcohort serves as the control
population and is representative of the entire cohort. All cases are evaluated, including those
that occur from within the subcohort and those that were not included in the subcohort
(Rothman & Greenland 1998). The case cohort design provides a direct estimate of the risk
ratio while reducing the number of ‘controls’ requiring evaluation. In our study, the subcohort
(controls) comprised a 65% sample of all HIV-infected children in the clinic (n = 400),
regardless of mortality status. All HIV-infected children who died or defaulted (cases) in the
clinic were included in the study population. Data were entered and stored in Microsoft Office
Access (Microsoft Corp., Redmond, WA, USA). The study was approved by the University
of North Carolina Institutional Review Board and the Malawi National Health Science
Research Committee.
Study setting
Kamuzu Central Hospital serves the central region of Malawi and is located in the capital city
of Lilongwe. The KCH paediatric HIV clinic was established in October 2004. This clinic
operated until November 2006, when the Malawi Baylor College of Medicine-Abbott Fund
Children's Clinical Centre of Excellence opened its HIV clinic and assumed care of the children.
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Subjects were all residents of Lilongwe or the central Malawi region. Children were eligible
for the study if they were <18 years of age and confirmed HIV-1 positive by either ELISA
antibody testing, HIV rapid tests, or DNA PCR. Patients were ART-naïve before referral to
the Paediatric HIV clinic at KCH. Children had to have initiated ART in the clinic by 15 May
2006 and had to be receiving a regimen of ART or have received ART until the date of their
death. The first-line anti-retroviral regimen in Malawi consists of a combination of nevirapine,
stavudine and lamivudine, with zidovudine and efavirenz as alternatives in case of intolerance
to first-line agents. The second-line regimen was not readily available at the time of this
evaluation. These regimens were in accordance with WHO ART guidelines at the time (WHO
2004) and the Malawi National ART guidelines (MoH Malawi 2006).
Children >18 months of age were eligible for ART if they were HIV-seropositive, if their
guardians understood the benefits and risks of ART, and if appropriate combinations of WHO
clinical stage, total lymphocyte, and CD4 cell count criteria were met (WHO 2004;MoH
Malawi 2006). Children <18 months of age were ART-eligible if they were HIV-seropositive,
in WHO stage III with a CD4 lymphocyte count <20%, or if they suffered from a clinical
condition (MoH Malawi 2006;Malawi Paediatric Anti-retroviral Treatment Group 2007).
Subjects were seen every 1–2 months in the clinic at KCH for check-ups and medication refills,
and as needed for acute illness. Care and management of these subjects was provided by
paediatricians from KCH, the University of North Carolina School of Medicine, and from
Baylor College of Medicine.
Data collection and measures
All subjects were enrolled at Kumuzu Central Hospital between October 2004 and May 2006.
Data were collected in June and July 2006 with a standardized form. Outcomes were
determined as of this date. Extracted data were entered into an MS Access database. The
variables recorded comprised
• demographic information (age, gender, residence, and main caregiver's relation to
child);
• health status at presentation, with ill at presentation defined as having one or more
HIV-related symptoms at the initial visit;
• clinical history with relation to HIV [initial signs and symptoms of HIV, AIDS-
defining illness, current or previous tuberculosis (TB) status, current medications, and
prevention of mother to child transmission status defined by the mother and infant
receiving prophylactic ART during pregnancy];
• family history (parents' HIV status, parents alive or dead, education status of parents,
distance to KCH as per caregiver, and how many children in household)
• laboratory studies as performed by KCH or UNC facilities (CD4 count and RNA viral
load pre- and post-ART)
• clinical staging of HIV in children and adolescents at ART initiation as defined by
WHO (2004) ART guidelines
• treatment course (ART start dates, duration of ART, reason of first-line failure, drug
allergies), and
• current status of the subject (alive, dead, cause of death, defaulter defined as having
missed their most recent scheduled appointment by >3 months, transferred, and/or
reason of transfer).
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Variables were recorded as applicable to the subject.
Orphan status was inferred by the mother's vital status. Reliable information on the father's
vital status was not typically documented, therefore mother's vital status was used as a proxy
for orphan status of the child.
Statistical methods
Statistical analysis was performed in order to determine which recorded variables, if any, were
associated with death or default among these patients. Our primary outcome was death or
default, based on the similarity of these groups and previous studies that have suggested that
the primary reason for a child to default was death (Hosseinipour et al. 2004; Brahmbhatt et
al. 2006). We also conducted a sensitivity analysis with an alternative outcome of death only.
We described the study population with frequencies for demographics, clinical conditions and
baseline laboratory values. We used α = 0.05 for significance testing. All statistical analyses
were performed using Stata 8.2 (Stata-Corp LP, College Station, TX, USA).
Cox proportional hazards modelling was used with the Prentice method to analyse these case
cohort data (Barlow et al. 1999). The time axis was days on ART. Alive children were right-
censored observations if death had not been reported by data review. Hazard ratios for
bivariable analyses were calculated after ensuring that the proportional hazards assumption
was not violated. For modelling purposes, only variables with fewer than 5% of values missing
were included in the analyses. We included all variables in the multivariable model without
further variable reduction.
Results
Characteristics of children on ART
From October 2004 to May 2006, 400 children were started on ART at Kumuzu Central
Hospital. A total of 258 files were reviewed during the retrospective analysis. Of the 258
reviewed patients, 185 (72%) were alive, 41 (16%) were deceased, and 32 (12%) had defaulted.
No children had transferred clinics.
The mean age of the cohort was 5.7 years; 79% were older than 18 months (Table 1). Thirteen
subjects were older than 13 years and 49% were male. At the time of ART initiation, 55% had
WHO stage III disease. The most common stage III conditions were pulmonary tuberculosis
(66%), severe recurrent bacterial pneumonia (11%), moderate malnutrition/weight loss (9%)
and oral thrush (8%). Among the stage IV conditions, severe failure to thrive or wasting (66%),
extrapulmonary tuberculosis (10%), recurrent severe bacterial infections (11%), and Kaposi's
sarcoma (9%) were the most common diagnoses. Sixteen per cent had lost both parents, 28%
had a living father but had lost their mother. Of those with a living father, 70% did not list their
father as the primary caregiver, but rather another member of the extended family. Twenty-
four per cent had active TB, 25% had a history of TB, and 47% had neither a history of nor
active TB. Thirteen per cent of the children had received single-dose nevirapine as a prevention
of mother to child transmission (PMTCT) regimen. Only 19% of the children were receiving
co-trimoxazole preventive therapy.
Treatment outcomes and correlates of mortality
The median duration of follow-up on ART overall was 196 days, based on the representative
subcohort (25th percentile = 105 days; 75th percentile = 310 days). In contrast, among children
who died or defaulted, the median duration of follow-up on ART was only 35 days (25th
percentile = 15 days; 75th percentile = 87 days).
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The mean age of children who had died (4.46 years) or defaulted (4.30 years) was younger
than that of survivors (6.14 years). The average weight of the population was 14.9 kg, with an
average of 11.9 kg in the deceased, 16.2 kg in the living, and 11.2 kg in the defaulters. Weight
loss at presentation was apparent in 94% of the deceased population and in 67% of the
defaulters, compared with 69% in survivors. Median CD4 counts were 332 [inter quartile range
(IQR) 174–590] cells/μl in survivors; 411 (IQR 59–1026) cells/μl in the deceased and 411 (IQR
234–800) in the defaulters. CD4 percentages were not available. Of the stage IV children, 54%
were deceased and among the stage III children, 41% were deceased.
In the multivariable Cox model, both age <18 months and being WHO stage IV remained
significantly associated with mortality and loss to follow-up. Children <18 months old were
2.15 times more likely to die as children aged at least 18 months (95% CI 1.00–4.61). Children
presenting with stage IV illness were 2.0 times as likely to die as those with stage I–III illness
(95% CI 1.07–3.76) (Table 2). Using dead vs. alive as the outcome excluding the defaulters
(Table 3), results show similar trends to the dead/defaulter vs. alive analysis (Table 2). Kaplan–
Meier estimates show significantly higher rate of death in the <18 months age category (Figure
1).
Discussion
Children receiving ART in Malawi experience high mortality compared with children in rich
countries (Resino et al. 2006; Judd et al. 2007). Their mortality appears to be greater than that
of adults in similar settings (Etard et al. 2006; Zachariah et al. 2006). Young age (<18 months)
and late WHO stage presentation were most strongly associated with mortality in our study.
Gender, being orphaned from the mother, or area of residence did not appear to play a predictive
role regarding mortality.
In adults on ART, most deaths occur within the first 3 months of treatment (Zachariah et al.
2006; Libamba et al. 2007). Children have been thought to follow similar trends (Bolton-Moore
et al. 2007; Boyd & Cooper 2007; Callens et al. 2009). Most deaths occurred within the first
100 days on treatment, particularly among the youngest patients. However, given that the
population was largely identified through hospital admissions, it may be expected to have a
relatively high mortality rate early on.
Age <18 months is associated with mortality when the defaulter population remains grouped
with the deceased, which is consistent with other studies (Violari et al. 2008). This trend
remained the same when defaulters were removed from the analysis, though precision was lost.
Rapid disease progression has been documented in perinatally infected infants (Eley et al.
2006) and delays in diagnosis are inevitable in this age group in settings where diagnosis is
dependent on antibody testing. This type of testing is well known to be unreliable in infants,
because it can reflect maternal antibodies. HIV DNA testing can accurately determine an
infant's status and could allow earlier initiation of anti-retroviral therapy in this age group.
However, earlier testing must be combined with Prevention of Mother to Child Transmission
programmes in order to ensure that all exposed infants are reached. We acknowledge that
children who initiated ART at older ages may have an additional survival advantage as they
have already managed to survive to the older age.
The association of WHO stage IV with mortality on multivariate modelling is similar to other
studies (Zachariah et al. 2006; Bong et al. 2007). Moreover, our cohort had an unexpectedly
high death rate among stage I patients, which may have influenced the findings. However, our
sample included very few stage I and stage II children and was insufficient to determine
gradations in mortality risk according to stage.
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Other studies have shown that weight or body mass index (BMI) is a good clinical predictor
of response to ART (Nyandiko et al. 2006; Zachariah et al. 2006). Likewise, total lymphocyte
count, low CD4 count, and low CD4 percentage predict mortality (HIV Paediatric Prognostic
Markers Collaborative Study 2005; Bong et al. 2007; Kiboneka et al. 2008). While our data
suggest that weight loss and low CD4 count are more commonly associated with death on
bivariable analysis, these variables were not included in multivariate modelling, as >5% of
values were missing from the patient records. Therefore, we are unable to know if these
variables independently predicted mortality in our study.
As community follow-up was not performed to confirm the status of the defaulters, we
conducted two analyses to determine how vital status influenced the results. Our findings
suggest that defaulters display characteristics more similar to dead children, particularly with
respect to duration on ART. Further, the marked similarity in the analysis when evaluating the
defaulters as assumed dead vs. excluded also suggests that defaulters are deceased. With a
greater sample size, we expect that the analysis would retain significance with regard to age
<18 months and WHO staging, given the high comparability of the dead and defaulter
populations and similar effect size. Several other studies also suggest defaulters are more likely
to be deceased in this setting (Hosseinipour et al. 2004; Brahmbhatt et al. 2006), Yu et al.
2007.
As a proxy for the orphan status of the child, we evaluated maternal vital status in our cohort
and did not find this to be associated with mortality. However, other studies have suggested
maternal health status may play a strong role in early death for children (Chearskul et al.
2002; Brahmbhatt et al. 2006; Marinda et al. 2007; Chilongozi et al. 2008). As our population
included only children who presented for ART care, we likely missed the population where
maternal health and vital status may have had the greatest impact. Further study of the health
status of the parents may be critical to understanding the high mortality rate in the <18 month
age group.
In this study, we were limited by the information contained on the clinic visit forms, which
were initially created for record keeping purposes at the Paediatric HIV Clinic at KCH.
Consequently, information could be recorded inconsistently and with varying skill and
experience of the clinicians. Staging itself may be somewhat unreliable in this setting.
Diagnoses such as the AIDS defining illness are often based upon clinical presentation and
rarely confirmed with sophisticated laboratory or radiographic data. Therefore it is also
possible that some of the children may have been staged incorrectly based on an erroneous
diagnosis. Although we limited the variables included in the Cox proportional hazards analyses
to those with at least 95% complete data, we could not account for measurement error
introduced by varying clinician performance.
The findings of this study suggest that earlier diagnosis in infants is critical, as late presentation
and advanced disease play a significant role in mortality. To improve outcomes among HIV-
positive children, clearly the <18 months age group must be specifically targeted and identified
with early identification techniques such as PCR DNA testing. The Malawi HIV program has
recognized this and is currently piloting an Early Infant Diagnosis program.
In poor settings these more expensive techniques may not be ideal. More novel techniques such
as p24 testing may be more feasible and also warrant further exploration (Cachafeiro et al.
2008). High mortality rates in the youngest children underscore the growing importance of
integrated prevention of mother to child transmission programs that emphasize optimal
regimens to maximize maternal health, prevent HIV transmission, and accurately diagnose
infant HIV infection as early as possible.
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Survival estimates according to age (P = 0.0003).
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Table 1
Characteristics at initial visit of children started on anti-retroviral therapy at Kumuzu Central Hospital in
Lilongwe, Malawi
Characteristics Total (n = 258) Dead/default (n = 73) Alive (n = 185)
n (%) n (%) n (%)
Gender
 Male 119 (48.80) 27 (39.10) 92 (52.60)
 Female 125 (51.20) 42 (60.90) 83 (47.40)
Age
 <18 months 55 (21.40) 27 (37.00) 28 (15.20)
 18 months–5 years 87 (33.90) 21 (28.80) 66 (35.90)
 >5 years–18 years 115 (44.70) 25 (34.20) 90 (48.90)
From Lilongwe
 Yes 186 (74.10) 55 (77.50) 131 (72.80)
 No 65 (25.90) 16 (22.50) 49 (27.20)
Mother alive
 Yes 164 (64.60) 53 (73.60) 111 (61.00)
 No 90 (35.40) 19 (26.40) 71 (39.00)
Ill at presentation
 Yes 142 (55.70) 50 (68.50) 92 (50.50)
 No 113 (44.30) 23 (31.50) 90 (49.50)
Weight loss
 Yes 170 (72.30) 52 (81.30) 118 (69.00)
 No 65 (27.70) 12 (18.80) 53 (31.00)
Fever
 Yes 67 (28.80) 16 (25.40) 51 (30.00)
 No 166 (71.20) 47 (74.60) 119 (70.00)
Diarrhoea
 Yes 56 (24.10) 18 (28.60) 38 (22.50)
 No 176 (75.90) 45 (71.40) 131 (77.50)
Developmental delay
 Yes 51 (22.60) 19 (31.10) 32 (19.40)
 No 175 (77.40) 42 (68.90) 133 (80.60)
Shingles
 Yes 37 (16.20) 6 (9.70) 31 (18.60)
 No 192 (83.80) 56 (90.30) 136 (81.40)
Oral candidiasis
 Yes 139 (59.90) 41 (66.10) 98 (57.60)
 No 93 (40.10) 21 (33.90) 72 (42.40)
Lymphadenopathy
 Yes 138 (63.60) 35 (61.40) 103 (64.40)
 No 79 (36.40) 22 (38.60) 57 (35.60)
Skin abnormalities
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Characteristics Total (n = 258) Dead/default (n = 73) Alive (n = 185)
n (%) n (%) n (%)
 Yes 154 (68.40) 45 (73.80) 109 (66.50)
 No 71 (31.60) 16 (26.20) 55 (33.50)
Tuberculosis
 Current TB 63 (24.90) 12 (16.90) 51 (28.00)
 Previous TB 65 (25.70) 16 (22.50) 49 (26.90)
 Suspected TB 3 (1.20) 2 (2.80) 1 (0.50)
 No TB 122 (48.20) 41 (57.70) 81 (44.50)
Co-trimoxazole prophylaxis
 Yes 50 (19.40) 21 (28.80) 29 (15.70)
 No 208 (80.60) 52 (71.20) 156 (84.30)
WHO stage
 Stage 1 7 (2.80) 5 (6.80) 2 (1.10)
 Stage 2 12 (4.70) 2 (2.70) 10 (5.50)
 Stage 3 142 (55.90) 27 (37.00) 115 (63.50)
 Stage 4 93 (36.60) 39 (53.40) 54 (29.80)
TB, tuberculosis; WHO, World Health Organization.
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Table 2
Unadjusted and adjusted hazard ratios for outcome of death/default by baseline characteristics
Unadjusted Adjusted
HR (95% CI) HR (95% CI)
Gender
 Male 0.60 (0.36, 1.01) 0.67 (0.36, 1.24)
 Female 1.00 – 1.00 –
Age
 <18 months 3.44 (1.88, 6.30) 2.15 (1.00, 4.61)
 18 months–5 years 1.18 (0.64, 2.16) 0.86 (0.41, 1.77)
 >5 years–18 years 1.00 – 1.00 –
From Lilongwe
 Yes 1.31 (0.73, 2.35) 1.61 (0.82, 3.19)
 No 1.00 – 1.00 –
Mother alive
 Yes 1.78 (1.03, 3.07) 1.92 (0.94, 3.92)
 No 1.00 – 1.00 –
Ill at presentation
 Yes 1.90 (1.12, 3.23) 1.03 (0.56, 1.89)
 No 1.00 – 1.00 –
Tuberculosis
 Active TB 0.54 (0.28, 1.02) 0.63 (0.30, 1.30)
 No active TB 1.00 – 1.00 –
Co-trimoxazole prophylaxis
 Yes 1.99 (1.13, 3.48) 1.47 (0.77, 2.78)
 No 1.00 – 1.00 –
WHO stage
 Stage 1, 2 or 3 1.00 – 1.00 –
 Stage 4 2.36 (1.44, 3.88) 2.00 (1.07, 3.76)
HR, hazard ratios; CI, confidence intervals; TB, tuberculosis; WHO, World Health Organization.
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Table 3
Unadjusted and adjusted hazard ratios for outcome of death by baseline characteristics (sensitivity analysis)
Unadjusted Adjusted
HR (95% CI) HR (95% CI)
Gender
 Male 0.73 (0.38, 1.40) 0.78 (0.37, 1.65)
 Female 1.00 – 1.00 –
Age
 <18 months 3.40 (1.58, 7.34) 2.79 (1.01, 7.73)
 18 months–5 years 1.20 (0.54, 2.64) 1.07 (0.40, 2.85)
 >5 years–18 years 1.00 – 1.00 –
From Lilongwe
 Yes 2.09 (0.86, 5.08) 2.09 (0.87, 5.01)
 No 1.00 – 1.00 –
Mother alive
 Yes 1.67 (0.82, 3.40) 1.52 (0.60, 3.86)
 No 1.00 – 1.00 –
Ill at presentation
 Yes 2.74 (1.31, 5.74) 1.70 (0.69, 4.20)
 No 1.00 – 1.00 –
Tuberculosis
 Active TB 0.57 (0.24, 1.31) 0.61 (0.25, 1.49)
 No active TB 1.00 – 1.00 –
Co-trimoxazole prophylaxis
 Yes 1.56 (0.74, 3.30) 1.08 (0.45, 2.60)
 No 1.00 – 1.00 –
WHO stage
 Stage 1, 2 or 3 1.00 – 1.00 –
 Stage 4 2.38 (1.25, 4.52) 1.68 (0.74, 3.78)
HR, hazard ratios; CI, confidence intervals; TB, tuberculosis; WHO, World Health Organization.
Note: Children who defaulted are included with the subcohort and are censored at the time of loss to follow-up.
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